A Study of RO5095932 in Patients With Type 2 Diabetes Mellitus
Status:
Completed
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
This randomized, double-blind, placebo-controlled study will assess the efficacy, safety,
tolerability, pharmacokinetics and pharmacodynamics of RO5095932 in patients with type 2
diabetes mellitus. Patients will be randomized to receive either RO5095932 subcutaneously
once weekly or placebo for 4 weeks (part 1) or 6 weeks (part 2), in addition to their current
stable doses of metformin.